121 related articles for article (PubMed ID: 38475670)
1. Comparison of valganciclovir
Zhu J; Xu M; Ru Y; Gong H; Ding Y; Zhu Z; Xu Y; Fan Y; Zhang X; Tu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu C; Chen S; Ma X; Chen F; Song T; Wu D; Chen J
Leuk Lymphoma; 2024 Jun; 65(6):816-824. PubMed ID: 38475670
[TBL] [Abstract][Full Text] [Related]
2. [Valganciclovir for treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation].
Wang Y; Huang XJ; Xu LP; Liu DH; Chen YH; Han W; Wang J; Liu KY
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(46):3265-7. PubMed ID: 19159551
[TBL] [Abstract][Full Text] [Related]
3. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
5. A clinical study of lyophilized intravenous human immunoglobulin containing high-titer cytomegalovirus-neutralizing antibody for the treatment of cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.
Zhang P; Yang D; Tian J; Feng S; Jiang E; Han M
Ann Palliat Med; 2021 May; 10(5):5533-5540. PubMed ID: 34107701
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
7. Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation.
Ke P; Bao X; Zhou J; Li X; Zhuang J; He X; Wu D; Zhang X; Ma X
Hematology; 2020 Dec; 25(1):43-47. PubMed ID: 31906810
[No Abstract] [Full Text] [Related]
8. Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34
Huang YT; Kim SJ; Lee YJ; Burack D; Nichols P; Maloy M; Perales MA; Giralt SA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1759-1766. PubMed ID: 28668490
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.
El Haddad L; Ghantoji SS; Park AK; Batista MV; Schelfhout J; Hachem J; Lobo Y; Jiang Y; Rondon G; Champlin R; Chemaly RF
J Med Virol; 2020 Jan; 92(1):86-95. PubMed ID: 31448830
[TBL] [Abstract][Full Text] [Related]
10. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
Minces LR; Nguyen MH; Mitsani D; Shields RK; Kwak EJ; Silveira FP; Abdel-Massih R; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Toyoda Y; Clancy CJ
Antimicrob Agents Chemother; 2014; 58(1):128-35. PubMed ID: 24145525
[TBL] [Abstract][Full Text] [Related]
11. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
[TBL] [Abstract][Full Text] [Related]
12. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
[TBL] [Abstract][Full Text] [Related]
13. Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Spinner ML; Lam SW; Koval CE; Athans V
J Clin Virol; 2019 Nov; 120():12-16. PubMed ID: 31514101
[TBL] [Abstract][Full Text] [Related]
14. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
[TBL] [Abstract][Full Text] [Related]
15. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.
Yoon JH; Lee S; Kim HJ; Jeon YW; Lee SE; Cho BS; Lee DG; Eom KS; Kim YJ; Min CK; Cho SG; Min WS; Lee JW
Oncotarget; 2016 Mar; 7(13):17230-41. PubMed ID: 26883100
[TBL] [Abstract][Full Text] [Related]
16. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Study of Allogeneic Hematopoietic Stem Cell Transplantation Patients with Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus].
Wang ZW; Liu Q; Sun HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):561-567. PubMed ID: 38660867
[TBL] [Abstract][Full Text] [Related]
19. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
